IMPACT OF COVID-19 VACCINATION ON OUTCOMES OF PATIENTS WITH SEVERE ACUTE RESPIRATORY SYNDROME: A RETROSPECTIVE COHORT STUDY IN THE FEDERAL DISTRICT (2020-2023)
DOI:
https://doi.org/10.47820/recima21.v5i8.5609Keywords:
Vaccination. COVID-19. SARS. Epidemiology. Public health.Abstract
Objective: This study seeks to analyze the relationship between COVID-19 vaccination and the outcomes of patients with severe acute respiratory syndrome (SARS) in the Federal District between 2020 and 2023. Method: We conducted a retrospective descriptive study using data on compulsory notification of SARS provided by the Management of Surveillance of Vaccine-preventable and Waterborne and Foodborne Diseases (GEVITHA). Information collected includes age, gender, vaccination status, comorbidities, and clinical outcomes. For statistical analysis, we used chi-square tests, logistic regression and multicollinearity analysis to verify the independence of the variables. Results: Our data show a significant difference in outcomes between the vaccinated and unvaccinated groups. Vaccination had an Odds Ratio (OR) of 0.064 (95% CI: 0.051-0.081), p < 0.001, indicating significant protection against severe outcomes. The need for ventilatory support and the presence of comorbidities, such as Down syndrome and immunosuppression, were also identified as important predictors of mortality. Multicollinearity analysis confirmed the robustness of the model without significant problems. Conclusion: Vaccination against COVID-19 is crucial in the prevention of severe infections, but it is not sufficient on its own to predict clinical outcomes in hospitalized patients with SARS. Effective management of SARS requires an integrated approach that considers multiple clinical factors, including vaccination, ventilatory support, and comorbidities. These findings underscore the need for comprehensive strategies in clinical practice and public health policymaking to address SARS during the COVID-19 pandemic.
Downloads
References
Abu-Raddad LJ, et al. Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar. JAMA. 2021;326(19):1930-1939. DOI: https://doi.org/10.1001/jama.2021.19623
Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Análise em Saúde e Vigilância de Doenças Não Transmissíveis. Síndrome Respiratória Aguda Grave (SRAG) - 2023. Brasília: Ministério da Saúde; 2023.
Hall VJ, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection: a prospective, multicentre, cohort study. Lancet. 2021;397(10286):1725-1735. DOI: https://doi.org/10.1016/S0140-6736(21)00790-X
Lopez Bernal J, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med. 2021;385:585-594. DOI: https://doi.org/10.1056/NEJMoa2108891
Oliveira AL, Farias LA, Santos RF, Almeida FJ. Eficácia e segurança da vacina BNT162b2 mRNA contra COVID-19 em crianças e adolescentes: uma revisão sistemática. Rev Saúde Pública. 2022;56:123-132.
Pereira MG, Fernandes LR, Silva RM. Análise de eficácia das vacinas contra COVID-19 na população idosa: um estudo observacional. J Bras Med. 2021;117:45-52.
Polack FP, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383:2603-2615. DOI: https://doi.org/10.1056/NEJMoa2034577
Sadoff J, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021;384:2187-2201. DOI: https://doi.org/10.1056/NEJMoa2101544
Tartof SY, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398(10309):1407-1416. DOI: https://doi.org/10.1016/S0140-6736(21)02183-8
Thompson MG, et al. Prevention and attenuation of Covid-19 with the BNT162b2 and mRNA-1273 vaccines. N Engl J Med. 2021;385:320-329. DOI: https://doi.org/10.1056/NEJMc2113575
World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: Interim guidance. Geneva: WHO; 2020. [Acesso em: 10 ago. 2023]; Disponível em: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. DOI: https://doi.org/10.15557/PiMR.2020.0003
Downloads
Published
How to Cite
License
Copyright (c) 2024 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
![Creative Commons License](http://i.creativecommons.org/l/by/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.